Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Gilles Renacco, the recently appointed general manager of Servier Turkey, provides insights into the successful localization process pioneered by Servier in the country, where 98 percent of the company’s products…
Christopher Gaunt, chairman of the British Chamber of Commerce in Turkey, analyzes the relationship between the two countries and the ongoing development of their relationship, in addition to how UK…
Bahadir Kaleagasi, secretary general of the Turkish Industry & Business Association (TÜSIAD) discusses the strengths of the country as Europe’s gateway to Asia in addition to the strong investment landscape…
Murat Üçer, reputed macroeconomist, former advisor to the Ministry of Economy, Global Source Partners’ consultant in Turkey, co-founder of Turkey Data Monitor, and senior lecturer at Koç University, dissects the…
Dr. Uğur Baran, general secretary of OHSAD – Turkey’s Private Hospital and Health Organizations Association – highlights how he is striving to keep open the dialogue between the association and…
Dr. Ümit Dereli and Cengiz Aydın of the Association of Research-Based Pharmaceutical Companies (AIFD) inTurkey discuss significant recent changes in the Turkish ecosystem, including the improving recognition of the country’s regulatory…
Below is a list of the Top 100 Pharma Companies in Turkey sorted by the total value of sales in USD for 2014. Global giant Novartis is number one in…
Despite a current lack of investment incentives; Turkey’s geographical location, market size, large and aging population, universal healthcare, potential future spending, and stage of economic development mean that it is…
Although the Turkish pharmaceutical market has grown significantly in recent years R&D investment remains comparatively low. However, the expertise and capabilities exist for growth in this sector. Turkish companies and…
In the first fifteen years of the 21st century Turkey saw rapid economic growth, greater access to healthcare, and a boom in pharmaceutical sales. The country’s healthcare sector is now…
Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and…
The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in…
See our Cookie Privacy Policy Here